ProfileGDS5678 / 1449679_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 88% 88% 88% 89% 87% 88% 89% 90% 87% 88% 89% 89% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.8656188
GSM967853U87-EV human glioblastoma xenograft - Control 26.9782588
GSM967854U87-EV human glioblastoma xenograft - Control 36.878888
GSM967855U87-EV human glioblastoma xenograft - Control 47.0995688
GSM967856U87-EV human glioblastoma xenograft - Control 57.0078489
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.512687
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.5954388
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.0322189
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.1133190
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.7885787
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.8653888
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.0981489
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.067689
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.8207788